S‑nitrosoglutathione treatment for newborn lung and airway injury
S-Nitrosoglutathione therapy for oxidant disease of the neonatal airways and lung
This project looks at whether giving a natural airway‑relaxing molecule called S‑nitrosoglutathione (GSNO) can help infants with bronchopulmonary dysplasia and other oxygen‑related lung injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11264877 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers are using newborn mouse models that mimic the oxygen‑related lung damage seen in premature infants to see if GSNO can reverse airway tightness and lung changes. They will study how an enzyme called GSNOR breaks down GSNO and how a small regulator (miR‑342) controls that enzyme. The team will compare mice treated with GSNO, mice lacking GSNOR, and normal mice to understand which cells and pathways drive disease. Findings are intended to guide whether GSNO‑based approaches could be moved toward studies in babies.
Who could benefit from this research
Good fit: Premature infants diagnosed with bronchopulmonary dysplasia or children with a history of neonatal oxygen exposure and ongoing airway hyperreactivity would be the most likely candidates.
Not a fit: Patients whose breathing problems are caused by unrelated issues like structural heart disease, acute infections, or non‑oxidant lung conditions are less likely to benefit from a GSNO‑targeted approach.
Why it matters
Potential benefit: If successful, this work could lead to a new therapy that eases airway narrowing, reduces inflammation, and lessens long‑term lung damage in premature infants with BPD.
How similar studies have performed: Preclinical mouse studies have shown GSNO reverses airway hyperreactivity and that loss of GSNOR is protective, but human clinical testing of this approach is limited.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Raffay, Thomas Michael — Case Western Reserve University
- Study coordinator: Raffay, Thomas Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.